FDA Grants Fast Track Designation to HiberCell’s HC-7366 for Acute Myeloid Leukemia Treatment
HiberCell, Inc., a clinical-stage biotechnology company focused on developing therapeutics to combat advanced cancer and cancer resistance, announced that the U.S. Food and Drug Administration (FDA) h ...
Vorasidenib Receives FDA Fast-Track Designation in Phase 3 INDIGO Trial for IDH-Mutant Low-Grade Glioma Treatment
Servier announced that its Vorasidenib has been granted FDA fast-track designation for its ability to prolong progression-free survival (PFS) and time to next intervention (TTNI) in patients with resi ...
Ikena Oncology’s IK-175 Receives FDA Fast Track Designation for Advanced Urothelial Carcinoma
Ikena Oncology, Inc. is a targeted oncology company that focuses on patient-directed cancer treatment has received Fast Track designation from the FDA for its drug IK-175, a novel aryl hydrocarbon rec ...